Literature DB >> 26375220

Quality of life in patients with oculocutaneous albinism.

Marcus Maia1, Beatrice Mussio Fornazier Volpini1, Gabriela Alves dos Santos1, Maria Josefa Penon Rujula1.   

Abstract

BACKGROUND: The social reality of the albino needs to be more studied in Brazil, as myths and social segregation regarding this illness are likely to be found in the country, with psychosocial and medical implications.
OBJECTIVE: As this subject has not been referenced in previous scientific articles in Brazil, this research intends to evaluate the quality of life of the albinos that treated at our medical institution.
METHODS: The quality of life was evaluated through the WHOQOL-BREF. Furthermore, two aspects of main relevance in the lives of the albinos were also objects of research, low vision and skin cancer. The sample consisted of forty oculocutaneous albinos and a control group of forty healthy individuals, matched by sex and age.
RESULTS: Among the participants, 57.7% were between 18 and 40 years old, 28.2% were between 41 and 60, and 14.1% were over 60. 42.1% had skin cancer before the study, 18.4% had skin cancer during the study and 89.5% stated visual deficit. The results obtained in the questionnaires showed a statistically significant difference in the physical domain, with P < 0.001.
CONCLUSION: Low vision combined with skin lesions and social stigma may contribute to disturbances in the quality of life of oculocutaneous albinos. The results presented in this study demonstrated the vulnerability of the affected individuals and the special care required by those patients, at the same time that the need for further research is highlighted in order to better elucidate the aspects related to albinism.

Entities:  

Mesh:

Year:  2015        PMID: 26375220      PMCID: PMC4560540          DOI: 10.1590/abd1806-4841.20153498

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  9 in total

1.  [Application of the Portuguese version of the instrument for the assessment of quality of life of the World Health Organization (WHOQOL-100)].

Authors:  M P Fleck; S Louzada; M Xavier; E Chachamovich; G Vieira; L Santos; V Pinzon
Journal:  Rev Saude Publica       Date:  1999-04       Impact factor: 2.106

2.  [Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref].

Authors:  M P Fleck; S Louzada; M Xavier; E Chachamovich; G Vieira; L Santos; V Pinzon
Journal:  Rev Saude Publica       Date:  2000-04       Impact factor: 2.106

Review 3.  Oculocutaneous albinism.

Authors:  J F Okulicz; R S Shah; R A Schwartz; C K Janniger
Journal:  J Eur Acad Dermatol Venereol       Date:  2003-05       Impact factor: 6.166

Review 4.  Albinism in Africa: stigma, slaughter and awareness campaigns.

Authors:  Andres E Cruz-Inigo; Barry Ladizinski; Aisha Sethi
Journal:  Dermatol Clin       Date:  2011-01       Impact factor: 3.478

Review 5.  Albinism: classification, clinical characteristics, and recent findings.

Authors:  C Gail Summers
Journal:  Optom Vis Sci       Date:  2009-06       Impact factor: 1.973

Review 6.  A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes.

Authors:  Clio Dessinioti; Alexander J Stratigos; Dimitris Rigopoulos; Andreas D Katsambas
Journal:  Exp Dermatol       Date:  2009-06-23       Impact factor: 3.960

Review 7.  Albinism and its implications with vision.

Authors:  Bradley J Kirkwood
Journal:  Insight       Date:  2009 Apr-Jun       Impact factor: 0.878

8.  Albinism in Africa as a public health issue.

Authors:  Esther S Hong; Hajo Zeeb; Michael H Repacholi
Journal:  BMC Public Health       Date:  2006-08-17       Impact factor: 3.295

Review 9.  Oculocutaneous albinism.

Authors:  Karen Grønskov; Jakob Ek; Karen Brondum-Nielsen
Journal:  Orphanet J Rare Dis       Date:  2007-11-02       Impact factor: 4.123

  9 in total
  7 in total

1.  Oral levodopa rescues retinal morphology and visual function in a murine model of human albinism.

Authors:  Helena Lee; Jennifer Scott; Helen Griffiths; Jay E Self; Andrew Lotery
Journal:  Pigment Cell Melanoma Res       Date:  2019-04-02       Impact factor: 4.693

Review 2.  [Oculocutaneous and ocular albinism].

Authors:  A S Kubasch; M Meurer
Journal:  Hautarzt       Date:  2017-11       Impact factor: 0.751

3.  Spectrum of skin diseases in Maroon villages of the Maroni area, French Guiana.

Authors:  Julie Valentin; Florence Niemetzky; Melanie Gaillet; Celine Michaud; Aurel Carbunar; Magalie Demar; Pierre Couppie; Romain Blaizot
Journal:  Int J Dermatol       Date:  2022-06-29       Impact factor: 3.204

Review 4.  Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review.

Authors:  Carlota Pascoal; Sandra Brasil; Rita Francisco; Dorinda Marques-da-Silva; Agnes Rafalko; Jaak Jaeken; Paula A Videira; Luísa Barros; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2018-11-28       Impact factor: 4.123

5.  Burden of albinism: development and validation of a burden assessment tool.

Authors:  Fanny Morice-Picard; Charles Taïeb; Aurelie Marti; Antoine Gliksohn; Mohammed Bennani; Christine Bodemer; Khaled Ezzedine
Journal:  Orphanet J Rare Dis       Date:  2018-09-18       Impact factor: 4.123

6.  Non-syndromic Oculocutaneous Albinism: Novel Genetic Variants and Clinical Follow Up of a Brazilian Pediatric Cohort.

Authors:  Laire Schidlowski; Fernando Liebert; Pérola Grupenmacher Iankilevich; Priscila Regina Orso Rebellato; Rafaela Andrade Rocha; Nadia Aparecida Pereira Almeida; Aayushee Jain; Yiming Wu; Yuval Itan; Roberto Rosati; Carolina Prando
Journal:  Front Genet       Date:  2020-04-28       Impact factor: 4.599

7.  Determining the Topic Evolution and Sentiment Polarity for Albinism in a Chinese Online Health Community: Machine Learning and Social Network Analysis.

Authors:  Qiqing Bi; Lining Shen; Richard Evans; Zhiguo Zhang; Shimin Wang; Wei Dai; Cui Liu
Journal:  JMIR Med Inform       Date:  2020-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.